- Acquired by MBody AI, Sep 2025
- Raised $35M funding round, Jun 2021
- Raised $10M funding round, Mar 2022
About
Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan, a patient-friendly, preparation-free screening test that enables early intervention and cancer prevention by detecting polyps before they may develop into colorectal cancer.
The company’s capsule-based screening technology is designed to significantly increase screening adherence worldwide, helping millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule; an integrated positioning, control, and recording system; and proprietary software to generate a 3D map of the inner lining of the colon as the capsule travels naturally along the gastrointestinal tract.
C-Scan is noninvasive and requires no sedation or bowel preparation, allowing patients to continue their daily routine without interruption. C-Scan is not intended to replace colonoscopies, and a positive C-Scan result should be followed by colonoscopy.
In March 2021, the FDA approved Check-Cap’s investigational device exemption application, permitting it to begin a pivotal study of C-Scan in the United States.
Funding history · 13 rounds · $134.2M total
Q&A
- What is Check-Cap's primary business?
- Check-Cap is a clinical-stage medical diagnostics company focused on redefining colorectal cancer (CRC) screening with its C-Scan, a capsule-based, preparation-free screening test.
- When was Check-Cap acquired and by whom?
- Check-Cap was acquired by MBody AI in September 2025.
- What is the C-Scan technology?
- The C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control, and recording system, and proprietary software to create a 3D map of the colon's inner lining for colorectal cancer screening.
- How many employees does Check-Cap have?
- Check-Cap has 32 employees, falling within the 11-50 employee bucket.
- What was a significant regulatory milestone for Check-Cap's C-Scan device?
- In March 2021, the FDA approved Check-Cap’s investigational device exemption application, allowing the company to begin a pivotal study of C-Scan in the United States.
- Who founded Check-Cap?
- Check-Cap was founded by Yoav Kimchy, who also serves as the CTO.
- What was Check-Cap's most recent funding round?
- Check-Cap raised $10,000,000 in March 2022.
- Which investors participated in Check-Cap's October 2014 funding round?
- Docor International Management, Pontifax, General Electric, and Shanghai Fosun Pharmaceutical participated in Check-Cap's October 2014 funding round.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | check-cap.com |
|---|---|
| linkedin.com/company/10085721 | |
| facebook.com/CheckCapLTD | |
| YouTube | youtube.com/channel/UC3n5N9eHCkwUyuEaSDQiXlA |
| Wikidata | wikidata.org/wiki/Q33121693 |
Identifiers & details
| Founded | 2005-1 |
|---|---|
| Employees (exact) | 32 |
| Market cap | $9.4M |
| Status reason | Acquired by MBody AI on Sep, 2025 |
| Wikidata QID | Q33121693 |
Acquisitions & public offerings
Acquired by MBody AI 2025-09
Radar intelligence
Patents
| EPO | 33 |
|---|
Web history (Wayback)
| Domain | check-cap.com |
|---|
Wikidata
| QID | Q33121693 |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|